Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q3 FY26 results · Oct–Dec 2025
Gufic Biosciences reported revenue from operations of ₹231.41 crore (up 11.4% from Q3 FY25) and net profit of ₹12.42 crore (down 35.6% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 231.41 | 207.79 | +11.4% | 237.05 | −2.4% |
| Other income | 0.79 | 1.86 | −57.6% | 2.12 | −62.6% |
| Total income | 232.20 | 209.66 | +10.8% | 239.17 | −2.9% |
| Profit before tax | 17.72 | 26.26 | −32.5% | 22.60 | −21.6% |
| Net profit for the period | 12.42 | 19.31 | −35.6% | 16.82 | −26.1% |
| EPS, basic (₹) | 1.24 | 1.93 | −35.8% | 1.68 | −26.2% |
| Net margin (%) | 5.4 | 9.3 | 7.1 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 231.09 | 207.79 | +11.2% | 230.42 | +0.3% |
| Other income | 0.79 | 1.86 | −57.4% | 2.09 | −62.1% |
| Total income | 231.89 | 209.66 | +10.6% | 232.51 | −0.3% |
| Profit before tax | 21.05 | 26.28 | −19.9% | 20.53 | +2.5% |
| Net profit for the period | 15.56 | 19.32 | −19.5% | 14.94 | +4.2% |
| EPS, basic (₹) | 1.55 | 1.93 | −19.7% | 1.49 | +4.0% |
| Net margin (%) | 6.7 | 9.3 | 6.5 |
Consolidated
- Filed with BSE
- 13 Feb 2026, 22:33 IST
- Board meeting
- 13 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Feb 2026, 22:33 IST
- Board meeting
- 13 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE